Dr. Yan Zhang 张琰
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized diagnosis and treatment of malignant lymphoma. Medical oncology for gastrointestinal cancers, lung cancer, and breast cancer.
Dr. Zhang holds a medical doctorate in oncology from the University of Worms, Germany (2008), a master’s in hematology from Southeast University Medical School (2005), and a bachelor’s in clinical medicine from the same institution (1998). Dr. Zhang was a visiting scholar in hematology and oncology at Heidelberg University, Germany, in 2011 and has nearly 20 years of experience in medical oncology.
Professional roles
- Youth Committee Member, Oncology Rehabilitation Branch, Chinese Society of Gerontology and Geriatrics
- Member, Translational Medicine Professional Committee, Jiangsu Immunological Society
- Member, Science Popularization Work Committee, Jiangsu Immunological Society
- Academic Secretary, Multidisciplinary Collaboration Group on Tumor Diagnosis and Treatment, Translational Medicine Professional Committee, Jiangsu Immunological Society
Name order: in Chinese the family name comes first (Zhang Yan). Papers usually list the name as Yan Zhang or Zhang Y.
Selected publications
40 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Carcinogenesis, 2024 (first author): Long non-coding RNA NRAV in the 12q24.31 risk locus drives gastric cancer development through glucose metabolism reprogramming. PubMed 37950445
- Ann Transl Med, 2022 (first author): Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study. PubMed 35813347
- Ann Transl Med, 2021 (senior author): COL11A1 promotes esophageal squamous cell carcinoma proliferation and metastasis and is inversely regulated by miR-335-5p. PubMed 34790783
- Aging (Albany NY), 2021 (first author): Linc00941 regulates esophageal squamous cell carcinoma via functioning as a competing endogenous RNA for miR-877-3p to modulate PMEPA1 expression. PubMed 34254950
- Curr Med Sci, 2021 (first author): Distinguishing Rectal Cancer from Colon Cancer Based on the Support Vector Machine Method and RNA-sequencing Data. PubMed 33877555
- J Transl Med, 2020 (senior author): Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study. PubMed 32513288
- Cancer Med, 2019 (senior author): LncRNA-LOC101928316 contributes to gastric cancer progression through regulating PI3K-Akt-mTOR signaling pathway. PubMed 31207155
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion